Computational drug design, synthesis, acetylcholinesterase inhibition and kinetic evaluation of novel benzothiazole-thiadiazole/oxadiazole derivatives.

IF 3.3 4区 医学 Q3 CHEMISTRY, MEDICINAL
Future medicinal chemistry Pub Date : 2026-10-01 Epub Date: 2026-10-06 DOI:10.1080/17568919.2026.2739927
Ramesh Ambatwar, Pooja Singh, Suman Ghosh, Lokesh Chandrakar, Ashok Kumar Datusalia, Gopal L Khatik
{"title":"Computational drug design, synthesis, acetylcholinesterase inhibition and kinetic evaluation of novel benzothiazole-thiadiazole/oxadiazole derivatives.","authors":"Ramesh Ambatwar, Pooja Singh, Suman Ghosh, Lokesh Chandrakar, Ashok Kumar Datusalia, Gopal L Khatik","doi":"10.1080/17568919.2026.2739927","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Developing novel benzothiazole-thiadiazole & oxadiazole hybrids as acetylcholinesterase (AChE) inhibitors.</p><p><strong>Material and methods: </strong>Benzothiazole-thiadiazole (<b>10a-n</b>) and benzothiazole-oxadiazole (<b>11a-p</b>) hybrids were synthesized and evaluated for AChE inhibition. The drug-likeness, molecular docking, molecular dynamics simulations, and cytotoxicity were also performed.</p><p><strong>Results: </strong>Compounds <b>10b</b>, <b>10d</b> and <b>10j</b> emerged as potent inhibitors, displaying IC<sub>50</sub> 0.05 µM, 0.12 µM and 0.14 µM, respectively. The IC<sub>50</sub> of compounds <b>11c</b>, <b>11f</b> and <b>11n</b> are 0.13 µM, 0.11 µM, and 0.09 µM, respectively, which are comparable to donepezil (IC<sub>50</sub> 0.03 µM). Further enzyme kinetic assays revealed a competitive inhibition mechanism. Drug-likeness, molecular docking and molecular dynamic simulation and cytotoxicity assays confirm the efficacy and safety profile.</p><p><strong>Conclusions: </strong>Benzothiazole-thiadiazole & oxadiazole scaffolds are promising leads for the developing AChE inhibitors.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2859-2876"},"PeriodicalIF":3.3000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652075/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2026.2739927","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Developing novel benzothiazole-thiadiazole & oxadiazole hybrids as acetylcholinesterase (AChE) inhibitors.

Material and methods: Benzothiazole-thiadiazole (10a-n) and benzothiazole-oxadiazole (11a-p) hybrids were synthesized and evaluated for AChE inhibition. The drug-likeness, molecular docking, molecular dynamics simulations, and cytotoxicity were also performed.

Results: Compounds 10b, 10d and 10j emerged as potent inhibitors, displaying IC50 0.05 µM, 0.12 µM and 0.14 µM, respectively. The IC50 of compounds 11c, 11f and 11n are 0.13 µM, 0.11 µM, and 0.09 µM, respectively, which are comparable to donepezil (IC50 0.03 µM). Further enzyme kinetic assays revealed a competitive inhibition mechanism. Drug-likeness, molecular docking and molecular dynamic simulation and cytotoxicity assays confirm the efficacy and safety profile.

Conclusions: Benzothiazole-thiadiazole & oxadiazole scaffolds are promising leads for the developing AChE inhibitors.

新型苯并噻唑-噻二唑/恶二唑衍生物的计算药物设计、合成、乙酰胆碱酯酶抑制及动力学评价。
目的:研制新型苯并噻唑-噻二唑和恶二唑类乙酰胆碱酯酶抑制剂。材料与方法:合成苯并噻唑-噻二唑(10a-n)和苯并噻唑-恶二唑(11a-p)复合物,并对其AChE抑制作用进行评价。并进行了药物相似、分子对接、分子动力学模拟和细胞毒性实验。结果:化合物10b、10d和10j为有效抑制剂,IC50分别为0.05、0.12和0.14µM。化合物11c、11f和11n的IC50分别为0.13µM、0.11µM和0.09µM,与多奈哌齐(IC50为0.03µM)相当。进一步的酶动力学分析揭示了竞争性抑制机制。药物相似性、分子对接、分子动力学模拟和细胞毒性试验证实了其有效性和安全性。结论:苯并噻唑-噻二唑和恶二唑支架是开发乙酰胆碱酯酶抑制剂的有前途的先导材料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书